Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
VBI Vaccines
VBI Vaccines
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Broughton receives flexible scope ISO 17025 accreditation
New certification allows accreditation without prior approval
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Regulatory
VBI Vaccines receives positive EMA Scientific Advice regarding Sci-B-Vac Phase III clinical Study
VBI Vaccines Inc. has received positive Scientific Advice for its Sci-B-Vac vaccine in Europe
Research & Development
VBI Vaccines appoints Dr Francisco Diaz-Mitoma as Chief Medical Officer
He will oversee clinical development initiatives at the firm
Research & Development
VBI Vaccines applies its eVLP platform to development of Zika vaccine
The eVLP platform enables the development of vaccines that mimic the structure of viruses found in nature
Research & Development
Sanofi Pasteur to use VBI technology to develop more stable vaccine candidate
French company has the option to acquire certain worldwide rights to LPV technology
Subscribe now